fda statement bpc-157 The just dropped a 68-page PDF on if should be legal or not to compound. Their initial recommendation: DO NOT add BPC-157 to the 503A Bulks List. They're meeting this The FDA panel will review

Journal of Psychiatric Research, 70 , 50-57

Lee SJ, Lee CK, Kang S, Park I, Kim YH, Kim SK, Hong SP, Bae H, He Y, Kubota Y, Koh GY

This product is intended for use under the supervision of a qualified healthcare professional

[DOI] [PubMed] [Google Scholar] Wang D

Monitoring recommendations: Baseline investigations: Full blood count, B12 level, folate, and intrinsic factor antibodies (if pernicious anaemia suspected) During initial treatment: Potassium monitoring in severe deficiency (risk of hypokalaemia) Follow-up: Repeat full blood count after 8 weeks to confirm haematological response Long-term: Annual review to ensure compliance with maintenance injections